Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2082 in Healthy Overweight or Obese Participants
NCT07532655Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing SYH2082 Injection with Placebo (2 arms). Primary endpoint: Number of Adverse Events at Day 85. Started Apr 2026; status: recruiting.
02
Drugs
SYH2082
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07532655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532655.